Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Chicago
Study ID
NCT03431948
Phase
PHASE1
Status
Completed

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    Nivolumab 240 mg given by intravenous infusion every 2 weeks
  • Cabiralizumab — DRUG
    Cabiralizumab 4 mg/kg given by intravenous infusion every 2 weeks
  • Urelumab — DRUG
    Urelumab 8 mg given by intravenous infusion every 4 weeks
  • Stereotactic Body Radiation Therapy — RADIATION
    Radiation to metastatic lesion(s) given at assigned dose levels based on lesion location and dose level being tested at time of enrollment. Doses range from 30 - 50 Gy.

Study Details

Study to determine the best dose of stereotactic body radiation therapy (SBRT) to be administered in combination with immunotherapy drugs including urelumab, cabiralizumab and nivolumab .

Key Dates

First listed
Feb 13, 2018
Start date
Mar 15, 2018
Status verified
Feb 2023
Primary completion
Feb 29, 2020
Completion
Apr 11, 2022

Study Design

Enrollment
60 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: SBRT with Nivolumab and Urelumab
    Patients will receive stereotactic body radiation therapy (SBRT) in combination with nivolumab and urelumab.
  • Experimental: SBRT with Nivolumab and Cabiralizumab
    Patients will receive stereotactic body radiation therapy (SBRT) in combination with nivolumab and cabiralizumab .

Primary Outcome Measure

Recommended dose of SBRT given in combination with immunotherapy [ Time Frame: 3 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Chicago Medical CenterChicagoIllinois60637-

Find similar trials in Chicago, IL

By research site
University of Chicago Medical Center· Chicago, IL

Related Studies